Overview

• An international Phase III study (BaxHTN) enrolled 796 adults across 214 clinics with uncontrolled or resistant hypertension despite multiple medications.
• After 12 weeks, baxdrostat 1 mg and 2 mg achieved placebo‑adjusted systolic reductions of 8.7 mmHg and 9.8 mmHg, respectively.
• About 40% of patients on baxdrostat reached guideline blood‑pressure targets compared with 18.7% on placebo.
• Safety findings were generally manageable, with rare hyperkalaemia reported in 1.1% of baxdrostat‑treated patients and occasional electrolyte changes.
• AstraZeneca plans to submit applications before year‑end 2025 targeting potential 2026 approvals in the US and EU, as rival lorundrostat showed a ~9.1 mmHg reduction and is also moving toward submission.